SCHOLTISSEN, S., Bruyère, O., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of glucosamine sulfate compared to acetaminophen in the treatment of knee osteoarthrits: a French health care perspective. Osteoporosis International, 21 (Suppl.1), 167. Peer Reviewed verified by ORBi |
SCHOLTISSEN, S., Bruyère, O., NEUPREZ, A., Severens, J. L., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2010). Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 64 (6), 756-62. doi:10.1111/j.1742-1241.2010.02362.x Peer Reviewed verified by ORBi |
Scholtissen, S., Guillemin, F., Bruyère, O., Collette, J., Dousset, B., Kemmer, C., Culot, S., Cremer, D., Dejardin, H., Hubermont, G., Lefebvre, D., Pascal-Vigneron, V., Weryha, G., & Reginster, J.-Y. (2009). Assessment of determinants for osteoporosis in elderly men. Osteoporosis International, 20 (7), 1157-66. doi:10.1007/s00198-008-0789-6 Peer Reviewed verified by ORBi |
Bruyère, O., SCHOLTISSEN, S., NEUPREZ, A., Hiligsmann, M., Toukouki, A., & Reginster, J.-Y. (2009). Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. Journal of Medical Economics, 12 (4), 356-360. doi:10.3111/13696990903438617 Peer Reviewed verified by ORBi |
NEUPREZ, A., Hiligsmann, M., Scholtissen, S., Bruyère, O., & Reginster, J.-Y. (2008). Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy, 25 (12), 1235-56. doi:10.1007/s12325-008-0125-8 Peer Reviewed verified by ORBi |